Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-MDR
2024-512763-32-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bedaquiline, pretomanid, linezolid, moxifloxacin and clofazimine in Tuberculosis (TB) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Sustained treatment success at 18 months in BPaLM arm vs historical cohort. Planned start Sep 2026; status: authorised.
02
Drugs
bedaquilinepretomanidlinezolidmoxifloxacinclofazimine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2024-512763-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512763-32-00.